Denali Therapeutics Inc
DNLI
Market Cap$2.23B
Close$
$0.77
95% downside
Current Fair Value
95% downsideOvervalued by 95% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.23 Billion |
|---|---|
| Enterprise Value | $2.14 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.57 |
| Beta | 1.36 |
| Outstanding Shares | 171,449,847 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.47 |
|---|---|
| PEG | -21.57 |
| Price to Sales | - |
| Price to Book Ratio | 3.09 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.09 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts